UBS analyst Eliana Merle raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $89.00 (from $87.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE